Published in The Lancet, the pivotal results of the LiGHT trial conclude that selective laser trabeculoplasty (SLT) should be used as the preferred first-line treatment for patients with glaucoma or ocular hypertension.1
Around the world, thousands of physicians are deploying this procedure as a primary therapy tool that stimulates the eye’s natural healing response to effectively manage their patients’ intraocular pressure without the burn and scar tissue associated with argon laser trabeculoplasty (ALT).
With Tango Neo you can use SLT to determine the location of the pathology and treat glaucoma effectively and safely for better patient outcomes.
Contact: salesadmin@ellex.com
Reference
- Gazzard G et al. LiGHT study, The Lancet. doi: 10.1016/S0140-6736(19)31503-X.
